Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Atsushi Hagino"'
Publikováno v:
Intestinal Research, Vol 16, Iss 2, Pp 255-266 (2018)
Background/AimsThis study compared the efficacy of multimatrix mesalazine 2.4 g/day and 4.8 g/day with controlled-release mesalazine 2.25 g/day.MethodsIn this multicenter, randomized, double-blind study, 251 patients with mildly to moderately active
Externí odkaz:
https://doaj.org/article/64c06188886845ba8526c8ab3aecf568
Autor:
Haruhiko Ogata, Akihiro Ohori, Haruo Nishino, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi
Publikováno v:
Intestinal Research, Vol 15, Iss 3, Pp 358-367 (2017)
Background/Aims: This study compared the efficacy of once-daily administration of multimatrix mesalazine 2.4 g/day with multiple-dose mesalazine for the maintenance of remission.Methods: In this multicenter, randomized, double-blind study, 203 patien
Externí odkaz:
https://doaj.org/article/f4a2d13947bf4559b2b006ae761b0887
Publikováno v:
Intestinal Research, Vol 15, Iss 3, Pp 368-379 (2017)
Background/Aims: This study assessed the efficacy and safety of high-dose multimatrix mesalazine once-daily (QD) compared to another form of high-dose mesalazine.Methods: In this multicenter, randomized, double-blind study, 280 patients with mildly t
Externí odkaz:
https://doaj.org/article/19a94261e7f4445b94cebd32b4ac569b
Publikováno v:
Intestinal Research
Intestinal Research, Vol 16, Iss 2, Pp 255-266 (2018)
Intestinal Research, Vol 16, Iss 2, Pp 255-266 (2018)
Background/aims This study compared the efficacy of multimatrix mesalazine 2.4 g/day and 4.8 g/day with controlled-release mesalazine 2.25 g/day. Methods In this multicenter, randomized, double-blind study, 251 patients with mildly to moderately acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ae33c0732145f4a619acbf735db953a
http://europepmc.org/articles/PMC5934598
http://europepmc.org/articles/PMC5934598
Autor:
Atsushi Hagino, Yeong Wook Song, Hiroaki Matsuno, Masato Tomomitsu, Seonghye Shin, Jiyoon Lee
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveTo evaluate the similarities between LBEC0101 (etanercept biosimilar) and the etanercept reference product (ETN-RP) in terms of efficacy and safety, including immunogenicity, in patients with active rheumatoid arthritis despite methotrexate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78327a10df61d50620fd6f0cc5fef55e
https://doi.org/10.1136/annrheumdis-2017-212172
https://doi.org/10.1136/annrheumdis-2017-212172
Publikováno v:
Journal of Obstetrics and Gynaecology Research. 43:1441-1448
Aim We aimed to investigate the safety and efficacy of dienogest (DNG), a progestational 19-norsteroid, administered for 52 weeks in patients with symptomatic adenomyosis. Methods A total of 130 patients with adenomyosis received 2 mg of DNG orally e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e161b713062918cbdc20324a7887821
https://doi.org/10.1111/jog.13406
https://doi.org/10.1111/jog.13406
Autor:
Masashi Sakaki, Kenichi Furihata, Kazuki Furuno, Kazuaki Inoue, Takafumi Yoshida, Atsushi Hagino, Takayoshi Ito, Yuji Kumagai, Shigeki Matsumoto
Publikováno v:
Clinical and Experimental Nephrology
Background Dotinurad is a novel, selective urate reabsorption inhibitor, which reduces serum uric acid levels by inhibiting the urate transporter 1 (URAT1). We compared the pharmacokinetics (PK), pharmacodynamics (PD), and safety of dotinurad in subj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7db4423c358e8944b9b54dbd82b11d5e
https://pubmed.ncbi.nlm.nih.gov/31760530
https://pubmed.ncbi.nlm.nih.gov/31760530
Publikováno v:
Neuropsychiatric Disease and Treatment
Satoshi Asakura,1 Taiji Hayano,2 Atsushi Hagino,2 Tsukasa Koyama3 1Health Care Center and Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 2Clinical Development Planning and Management, Mochida Pharmaceuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9027810a88b188721730c5e4177c89d0
https://doi.org/10.2147/ndt.s108983
https://doi.org/10.2147/ndt.s108983
Publikováno v:
The journal of obstetrics and gynaecology research. 43(9)
We aimed to investigate the safety and efficacy of dienogest (DNG), a progestational 19-norsteroid, administered for 52 weeks in patients with symptomatic adenomyosis.A total of 130 patients with adenomyosis received 2 mg of DNG orally each day for 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a687129669d3ea39165a2ba2f04c9008
https://pubmed.ncbi.nlm.nih.gov/28737239
https://pubmed.ncbi.nlm.nih.gov/28737239
Publikováno v:
Fertility and sterility. 108(4)
To evaluate the efficacy and safety of dienogest (DNG), a progestational 19-norsteroid, in patients with symptomatic adenomyosis.Phase III, randomized, double-blind, multicenter, placebo-controlled study.Clinical study sites in Japan.Sixty-seven pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a22520a6680c4b8c1db07a1d2f2e6dbc
https://pubmed.ncbi.nlm.nih.gov/30268309
https://pubmed.ncbi.nlm.nih.gov/30268309